GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 4496-4505

  Mohr, Emma L ^a,b   Xiang, Jinhua ^a   McLinden, James H ^a   Kaufman, Thomas M ^a   Chang, Qing ^a   Montefiori, David C ^c   Klinzman, Donna ^a   Stapleton, Jack T ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E2; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; GAG PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MOUSE; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOTYPING; SURVIVAL; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ISOLATION; YELLOW FEVER FLAVIVIRUS; ANIMAL; CELL SEPARATION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPRECIPITATION; MOLECULAR MIMICRY; RABBIT; VIRION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL SEPARATION; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GB VIRUS C; HIV-1; HUMANS; IMMUNOPRECIPITATION; MICE; MOLECULAR MIMICRY; RABBITS; VIRAL ENVELOPE PROTEINS; VIRION;

EID: 77958121295     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001980     Document Type: Article

References (68)

1. Fauci, A. S., M. I. Johnston, C. W. Dieffenbach, D. R. Burton, S. M. Hammer, J. A. Hoxie, M. Martin, J. Overbaugh, D. I. Watkins, A. Mahmoud, and W. C. Greene. 2008. HIV vaccine research: the way forward. Science 321:530-532.
2. Johnston, M. I., and A. S. Fauci. 2008. An HIV vaccine-challenges and prospects. N. Engl. J. Med. 359:888-890.
3. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10:359-369.
4. Dennison, S. M., S. M. Stewart, K. C. Stempel, H.-X. Liao, B. F. Haynes, and S. M. Alam. 2009. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J. Virol. 83:10211-10223.
5. Wild, C., T. Greenwell, and T. Matthews. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9:1051-1053.
6. Ferrantelli, F., R. Hofmann-Lehmann, R. A. Rasmussen, T. Wang, W. Xu, P.-L. Li, D. C. Montefiori, L. A. Cavacini, H. Katinger, G. Stiegler, et al. 2003. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17:301-309.
7. Sánchez-Martínez, S., M. Lorizate, K. Hermann, R. Kunert, G. Basañez, and J. L. Nieva. 2006. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 580:2395-2399.
8. Haynes, B. F., and S. M. Alam. 2008. HIV-1 hides an Achilles' heel in virion lipids. Immunity 28:10-12.
9. Coutant, J., H. Yu, M.-J. Clément, A. Alfsen, F. Toma, P. A. Curmi, and M. Bomsel. 2008. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J. 22:4338-4351.
10. Haynes, B. F., J. Fleming, E. W. St. Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
11. Matyas, G. R., Z. Beck, N. Karasavvas, and C. R. Alving. 2009. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta 1788:660-665.
12. Matyas, G. R., L. Wieczorek, Z. Beck, C. Ochsenbauer-Jambor, J. C. Kappes, N. L. Michael, V. R. Polonis, and C. R. Alving. 2009. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 23:2069-2077.
13. Ruprecht, R. M., F. Ferrantelli, M. Kitabwalla, W. Xu, and H. M. McClure. 2003. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 21:3370-3373.
14. Koff, W. C. 2010. Accelerating HIV vaccine development. Nature 464:161-162.
15. George, S. L., D. Varmaz, and J. T. Stapleton. 2006. GB virus C replicates in primary T and B lymphocytes. J. Infect. Dis. 193:451-454.
16. Stapleton, J. T. 2003. GB virus type C/Hepatitis G virus. Semin. Liver Dis. 23:137-148.
17. Stapleton, J. T., C. F. Williams, and J. Xiang. 2004. GB virus type C: a beneficial infection? J. Clin. Microbiol. 42:3915-3919.
18. Lefrère, J. J., F. Roudot-Thoraval, L. Morand-Joubert, J.-C. Petit, J. Lerable, M. Thauvin, and M. Mariotti. 1999. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J. Infect. Dis. 179:783-789.
19. Xiang, J., S. Wünschmann, D. J. Diekema, D. Klinzman, K. D. Patrick, S. L. George, and J. T. Stapleton. 2001. Effect of coinfection with GB virus C on survival among patients with HIV infection. N. Engl. J. Med. 345:707-714.
20. Tillmann, H. L., H. Heiken, A. Knapik-Botor, S. Heringlake, J. Ockenga, J. C. Wilber, B. Goergen, J. Detmer, M. McMorrow, M. Stoll, et al. 2001. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345:715-724.
21. Van der Bij, A. K., N. Kloosterboer, M. Prins, B. Boeser-Nunnink, R. B. Geskus, J. M. A. Lange, R. A. Coutinho, and H. Schuitemaker. 2005. GB virus C coinfection and HIV-1 disease progression: the Amsterdam Cohort Study. J. Infect. Dis. 191:678-685.
22. Zhang, W., K. Chaloner, H. L. Tillmann, C. F. Williams, and J. T. Stapleton. 2006. Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV Med. 7:173-180.
23. Supapol, W. B., R. S. Remis, J. Raboud, M. Millson, J. Tappero, R. Kaul, P. Kulkarni, M. S. McConnell, P. A. Mock, M. Culnane, et al. 2008. Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection. J. Infect. Dis. 197:1369-1377.
24. Handelsman, E., I. Cheng, B. Thompson, R. Hershow, L. M. Mofenson, F. B. Hollinger, K. T. Chen, S. K. Burchett, D. Klinzman, J. T. Stapleton, et al. 2007. Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. HIV Med. 8:561-567.
25. [Published erratum in 2008 HIV Med. 9:64.]
26. Williams, C. F., D. Klinzman, T. E. Yamashita, J. Xiang, P. M. Polgreen, C. Rinaldo, C. Liu, J. Phair, J. B. Margolick, D. Zdunek, et al. 2004. Persistent GB virus C infection and survival in HIV-infected men. N. Engl. J. Med. 350:981-990.
27. McLinden, J. H., T. M. Kaufman, J. Xiang, Q. Chang, D. Klinzman, A. M. Engel, G. Hess, U. Schmidt, M. Houghton, and J. T. Stapleton. 2006. Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. J. Virol. 80:12131-12140.
28. Schmolke, S., M. Tacke, U. Schmitt, A. M. Engel, and B. Ofenloch-Haehnle. 1998. Identification of hepatitis G virus particles in human serum by E2-specific monoclonal antibodies generated by DNA immunization. J. Virol. 72:4541-4545.
29. Larios, C., J. Casas, M. A. Alsina, C. Mestres, M. J. Gómara, and I. Haro. 2005. Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein. Arch. Biochem. Biophys. 442:149-159.
30. Larios, C., J. Casas, C. Mestres, I. Haro, and M. A. Alsina. 2005. Perturbations induced by synthetic peptides from hepatitis G virus structural proteins in lipid model membranes: a fluorescent approach. Luminescence 20:279-281.
31. Herrera, E., M. J. Gomara, S. Mazzini, E. Ragg, and I. Haro. 2009. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide. J. Phys. Chem. B 113:7383-7391.
32. Jung, S., M. Eichenmüller, N. Donhauser, F. Neipel, A. M. Engel, G. Hess, B. Fleckenstein, and H. Reil. 2007. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 21:645-647.
33. Mohr, E. L., and J. T. Stapleton. 2009. GB virus type C interactions with HIV: the role of envelope glycoproteins. J. Viral Hepat. 16:757-768.
34. Xiang, J., S. Wünschmann, W. N. Schmidt, J. Shao, and J. T. Stapleton. 2000. Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J. Virol. 74:9125-9133.
35. Wünschmann, S., and J. T. Stapleton. 2000. Fluorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia. J. Clin. Microbiol. 38:3055-3060.
36. Xiang, J., S. L. George, S. Wünschmann, Q. Chang, D. Klinzman, and J. T. Stapleton. 2004. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1. Lancet 363:2040-2046.
37. Montefiori, D. 2004. Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. In Current Protocols in Immunololgy. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Sevach, W. Strober, and R. Coico, eds. John Wiley & Sons, New York, NY, p. 11.1-11.5.
38. Jamieson, B. D., and J. A. Zack. 1998. In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J. Virol. 72:6520-6526.
39. Roth, M. D., K. M. Whittaker, R. Choi, D. P. Tashkin, and G. C. Baldwin. 2005. Cocaine and s-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J. Leukoc. Biol. 78:1198-1203.
40. Sinn, P. L., M. A. Hickey, P. D. Staber, D. E. Dylla, S. A. Jeffers, B. L. Davidson, D. A. Sanders, and P. B. McCray, Jr. 2003. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor a. J. Virol. 77:5902-5910.
41. Bae, H. G., A. Nitsche, A. Teichmann, S. S. Biel, and M. Niedrig. 2003. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. J. Virol. Methods 110:185-191.
42. Sakata, H., M. Hishiyama, and A. Sugiura. 1984. Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines. J. Clin. Microbiol. 19:21-25.
43. Mantel, N., M. Aguirre, S. Gulia, Y. Girerd-Chambaz, S. Colombani, C. Moste, and V. Barban. 2008. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J. Virol. Methods 151:40-46.
44. Akiyama, M., H. Kimura, H. Tsukagoshi, K. Taira, K. Mizuta, M. Saitoh, M. Nagano, A. Sutoh, M. Noda, Y. Morita, et al. 2009. Development of an assay for the detection and quantification of the measles virus nucleoprotein (N) gene using real-time reverse transcriptase PCR. J. Med. Microbiol. 58:638-643.
45. Kaufman, T. M., J. H. McLinden, J. Xiang, A. M. Engel, and J. T. Stapleton. 2007. The GBV-C envelope glycoprotein E2 does not interact specifically with CD81. AIDS 21:1045-1048.
46. Wünschmann, S., J. D. Medh, D. Klinzmann, W. N. Schmidt, J. T. Stapleton, and J. T. Stapleton. 2000. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J. Virol. 74:10055-10062.
47. Xiang, J., C. Martinez-Smith, M. Gale, Jr., Q. Chang, D. R. Labrecque, W. N. Schmidt, and J. T. Stapleton. 2005. GB virus type C NS5A sequence polymorphisms: association with interferon susceptibility and inhibition of PKR-mediated eIF2α phosphorylation. J. Interferon Cytokine Res. 25:261-270.
48. Geonnotti, A. R., M. Bilska, X. Yuan, C. Ochsenbauer, T. G. Edmonds, J. C. Kappes, H. X. Liao, B. F. Haynes, and D. C. Montefiori. 2010. Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res. Hum. Retroviruses 26:279-291.
49. Polonis, V. R., H. Schuitemaker, E. M. Bunnik, B. K. Brown, and G. Scarlatti. 2009. Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr. Opin. HIV AIDS 4:400-407.
50. Fenyö, E. M., A. Heath, S. Dispinseri, H. Holmes, P. Lusso, S. Zolla-Pazner, H. Donners, L. Heyndrickx, J. Alcami, V. Bongertz, et al. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4: e4505.
51. Mascola, J. R., P. D'Souza, P. Gilbert, B. H. Hahn, N. L. Haigwood, L. Morris, C. J. Petropoulos, V. R. Polonis, M. Sarzotti, and D. C. Montefiori. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79:10103-10107.
52. Polonis, V. R., B. K. Brown, A. Rosa Borges, S. Zolla-Pazner, D. S. Dimitrov, M.-Y. Zhang, S. W. Barnett, R. M. Ruprecht, G. Scarlatti, E.-M. Fenyö, et al. 2008. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375:315-320.
53. Tacke, M., S. Schmolke, V. Schlueter, S. Sauleda, J. I. Esteban, E. Tanaka, K. Kiyosawa, H. J. Alter, U. Schmitt, G. Hess, et al. 1997. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology 26:1626-1633.
54. Linnen, J., J. Wages, Jr., Z.-Y. Zhang-Keck, K. E. Fry, K. Z. Krawczynski, H. Alter, E. Koonin, M. Gallagher, M. Alter, S. Hadziyannis, et al. 1996. Molecular cloning and disease association of hepatitis G virus: a transfusiontransmissible agent. Science 271:505-508.
55. Simons, J. N., T. P. Leary, G. J. Dawson, T. J. Pilot-Matias, A. S. Muerhoff, G. G. Schlauder, S. M. Desai, and I. K. Mushahwar. 1995. Isolation of novel virus-like sequences associated with human hepatitis. Nat. Med. 1:564-569.
56. Menendez, A., K. C. Chow, O. C. C. Pan, and J. K. Scott. 2004. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J. Mol. Biol. 338:311-327.
57. Huarte, N., M. Lorizate, R. Kunert, and J. L. Nieva. 2008. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies. FEBS Lett. 582:3798-3804.
58. + T cell preservation, and GBV-C viral load (VL) is weakly inversely related to HIV VL. Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, New South Wales, Australia, July 22-27, 2007.
59. Galéa, P., C. le Contel, C. Coutton, and J.-C. Chermann. 1999. Rationale for a vaccine using cellular-derived epitope presented by HIV isolates. Vaccine 17:1700-1705.
60. Doria-Rose, N. A., R. M. Klein, M. G. Daniels, S. O'Dell, M. Nason, A. Lapedes, T. Bhattacharya, S. A. Migueles, R. T. Wyatt, B. T. Korber, et al. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
61. Sei, Y., P. H. Tsang, J. P. Roboz, P. S. Sarin, J. I. Wallace, and J. G. Bekesi. 1988. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study. J. Clin. Immunol. 8:464-472.
62. Lopalco, L., C. Barassi, C. Pastori, R. Longhi, S. E. Burastero, G. Tambussi, F. Mazzotta, A. Lazzarin, M. Clerici, and A. G. Siccardi. 2000. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals downmodulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J. Immunol. 164:3426-3433.
63. Hasselrot, K., G. Bratt, T. Hirbod, P. Säberg, M. Ehnlund, L. Lopalco, E. Sandström, and K. Broliden. 2010. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. AIDS 24:35-43.
64. Hasselrot, K., P. Säberg, T. Hirbod, J. Söderlund, M. Ehnlund, G. Bratt, E. Sandström, and K. Broliden. 2009. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 23:329-333.
65. Mazzoli, S., L. Lopalco, A. Salvi, D. Trabattoni, S. Lo Caputo, F. Semplici, M. Biasin, C. Bl, A. Cosma, C. Pastori, et al. 1999. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J. Infect. Dis. 180:871-875.
66. Heuft, H. G., T. Berg, E. Schreier, U. Künkel, M. Tacke, N. Schwella, U. Hopf, A. Salama, and D. Huhn. 1998. Epidemiological and clinical aspects of hepatitis G virus infection in blood donors and immunocompromised recipients of HGV-contaminated blood. Vox Sang. 74:161-167.
67. Pilot-Matias, T. J., R. J. Carrick, P. F. Coleman, T. P. Leary, T. K. Surowy, J. N. Simons, A. S. Muerhoff, S. L. Buijk, M. L. Chalmers, G. J. Dawson, et al. 1996. Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology 225:282-292.
68. Blankson, J. N., D. Klinzman, J. Astemborski, D. L. Thomas, G. D. Kirk, and J. T. Stapleton. 2008. Low frequency of GB virus C viremia in a cohort of HIV-1-infected elite suppressors. AIDS 22:2398-2400.